Announced Wed, 29 Apr · 18:53 IST
Syngene appoints two independent directors, reappoints Vinita Bali
Management Changes View source PDF
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+13.6%1-day move
₹431.40
prior close
₹431.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+9.2+11.2+8.6+9.4+13.6+4.6+4.3+8.0+6.8+10.7+7.2+4.3+2.1—
Up moveDown movePending
AI summary
Syngene's Board approved appointing Mr. Vijaya Chandru (MIT PhD, co-founder of Strand Life Sciences, AI/computational biology expert) and Mr. Arun Chandavarkar (former CEO & JMD of Biocon) as Independent Non-Executive Directors for 3-year terms from the 33rd AGM on July 29, 2026. Ms. Vinita Bali reappointed as Non-Executive Director for one year from July 22, 2026. All subject to shareholder approval; none debarred by SEBI.
Likely market impact
Strengthens board with biotech and global business expertise; positive governance signal, no disruption.